ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
eFFECTOR and QBI to study anti-viral agent for Covid-19 treatment pharmaceutical-technology
May 06, 2021eFFECTOR Therapeutics and Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), have announced a $5m cooperative agreement for a planned Phase Ib study of zotatifin (eFT226), an anti-viral agent for Covid-19 ... -
Pfizer signs oncology agreement with STR-focused eFFECTOR pharmaceutical-technology
January 14, 2020San Diego-based eFFECTOR has signed an exclusive worldwide license and collaboration agreement with Pfizer in the oncology field. The collaboration focuses on the development of small molecule inhibitors of eukaryotic initiation factor 4E (elF4E) ... -
eFFECTOR Therapeutics completes $38.6 million Series C financing
biospectrumasia
August 11, 2017Pfizer Venture Investments (PVI) led the round and was joined by additional new investors including Alexandria Venture Investments.
Pharma Sources Insight January 2025
